1 week Ago By ABMN Staff
JPMorgan Chase & Co. cut its stake in Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT – Free Report ) by 12.
0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,141,505 shares of the company’s stock after selling 155,406 shares during the period. JPMorgan Chase & Co.
’s holdings in Arcutis Biotherapeutics were worth $15,901,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently bought and sold shares of ARQT. Venturi Wealth Management LLC purchased a new stake in shares of Arcutis Biotherapeutics in the fourth quarter valued at $46,000.
Cibc World Markets Corp bought a new position in Arcutis Biotherapeutics during the 4th quarter valued at about $140,000. LVW Advisors LLC purchased a new stake in Arcutis Biotherapeutics in the 4th quarter worth about $166,000. Aigen Investment Management LP bought a new stake in Arcutis Biotherapeutics in the fourth quarter worth about $191,000.
Finally, KLP Kapitalforvaltning AS bought a new stake in Arcutis Biotherapeutics in the fourth quarter worth about $337,000. Arcutis Biotherapeutics Price Performance ARQT opened at $12.59 on Friday.
The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -7.03 and a beta of 1.
67. The company has a current ratio of 2.46, a quick ratio of 2.
38 and a debt-to-equity ratio of 0.67. Arcutis Biotherapeutics, Inc.
has a 12-month low of $6.99 and a 12-month high of $17.75.
The business’s fifty day simple moving average is $14.23 and its 200-day simple moving average is $12.60.
Insider Transactions at Arcutis Biotherapeutics In other news, Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $12.
71, for a total value of $127,100.00. Following the transaction, the director now directly owns 141,944 shares in the company, valued at approximately $1,804,108.
24. This trade represents a 6.58 % decrease in their position.
The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink . Also, insider Todd Franklin Watanabe sold 1,500 shares of the company’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $17.
52, for a total value of $26,280.00. Following the sale, the insider now owns 927,414 shares of the company’s stock, valued at $16,248,293.
28. This trade represents a 0.16 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . In the last quarter, insiders sold 46,099 shares of company stock valued at $631,256. Company insiders own 9.
50% of the company’s stock. Wall Street Analysts Forecast Growth Several equities research analysts have recently weighed in on the company. Guggenheim reiterated a “buy” rating on shares of Arcutis Biotherapeutics in a report on Thursday, April 3rd.
Mizuho increased their target price on Arcutis Biotherapeutics from $20.00 to $21.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 26th.
Jefferies Financial Group lifted their target price on Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Tuesday, March 11th.
HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Arcutis Biotherapeutics in a report on Thursday, April 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $20.
00 price objective on shares of Arcutis Biotherapeutics in a report on Wednesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.
com, Arcutis Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $18.80. Check Out Our Latest Research Report on ARQT About Arcutis Biotherapeutics ( Free Report ) Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. Further Reading Want to see what other hedge funds are holding ARQT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcutis Biotherapeutics, Inc.
( NASDAQ:ARQT – Free Report ). Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
